“Guidelines updated on Friday add Kyprolis in combo with Revlimid & Dex as an option for patients who are transplant candidates with a category 2A classification (low-evidence but uniform NCCN consensus). It has been included as an ‘other regimen.’ We are not sure what differences there are in other vs. preferred for ease of reimbursement, but we think that inclusion as other is definitely a positive first step.,” the firm’s analyst wrote.
Onyx Pharmaceuticals opened at 87.83 on Monday. Onyx Pharmaceuticals has a 52-week low of $36.53 and a 52-week high of $93.18. The stock’s 50-day moving average is currently $77.44. The company’s market cap is $6.324 billion.
Other equities research analysts have also recently issued reports about the stock. Analysts at Morgan Stanley reiterated an equal weight rating on shares of Onyx Pharmaceuticals in a research note to investors on Monday. Separately, analysts at Jefferies Group reiterated a buy rating on shares of Onyx Pharmaceuticals in a research note to investors on Monday. They now have a $96.00 price target on the stock. Finally, analysts at Zacks downgraded shares of Onyx Pharmaceuticals from an outperform rating to a neutral rating in a research note to investors on Friday, March 8th. They now have a $88.00 price target on the stock.
Sixteen equities research analysts have rated the stock with a buy rating, two have issued an overweight rating, and four have issued a hold rating to the company. The stock has a consensus rating of buy and a consensus price target of $101.18.
Onyx Pharmaceuticals, Inc. (Onyx) is a biopharmaceutical company. The Company is developing therapies that target the molecular mechanisms that cause cancer.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.